Mordin M, Parrish W, Masaquel C, Bisson B, Copley-Merriman K. Intra-articular hyaluronic acid for osteoarthritis of the knee in the United States: a systematic review of economic evaluations. Clin Med Insights Arthritis Musculoskelet Disord. 2021 Nov 19;14:1-13. doi: 10.1177/11795441211047284
Copley-Merriman C, Mordin M. Use of pragmatic clinical trials in reimbursement decisions. In: Girman, CJ, Ritchey, ME, editors. Pragmatic randomized clinical trials: using primary data collection and electronic health records. 1st ed. Waltham: MA. Academic Press; 2021. p.445-60.
Khan S, Mordin M, Barrows SB, Copley-Merriman K. Similarities & differences in Global Value Dossier (GVD) and Academy of Managed Care Pharmacy (AMCP) dossier development. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.
Mordin M, Fernandez M, Pearson I, Copley-Merriman K, McBride D. Similarities and differences in European HTA evidence requirements: one for all or one for none? Presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.
Fernandez MM, Khan S, Mordin M, Copley-Merriman C, McBride D. Comparing literature review requirements for reimbursement submissions across the globe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.732
Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014 Oct 16;4(10):e005150. doi: 10.1136/bmjopen-2014-005150
Copley-Merriman C, Zelt S, Stone G, Barrows SM, Mordin MM, Hogue SL. Emerging-market payer needs: how should these countries be included in dermatology drug development plans? Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.
Mordin M, Copley-Merriman C, Mauskopf J, Sweeney C, Bhattacharyya S, Farup C, Beach W, Higgins L, McIntyre L. Surgical innovation: do we need a more balanced framework for evidence? Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 3, 2013. [abstract] Value Health. 2013 May; 16(3):A247.
McIntyre LF, Beach WR, Higgins LD, Mordin MM, Mauskopf J, Sweeney CT, Copley-Merriman C. Evidence-based medicine, appropriate-use criteria, and sports medicine: how best to develop meaningful treatment guidelines. Arthroscopy. 2013 Mar 18;29(7):1224-9.
Mauskopf J, Beach W, McIntyre L, Bhattacharyya S, Higgins L, Mordin M, Copley-Merriman K. Evidence-based medicine: a case study of its application to innovative surgical procedures in the United Kingdom. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 7, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A408.
DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and niologic license applications, 2006-2010. Value Health. 2012 May 1;15(3):443-8.
Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012 May;15(3):437-42. doi: 10.1016/j.jval.2011.11.032
Mordin M, Clark M, DeMuro C, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Pro label claims: an analysis based on a review of pros among new molecular entities and biologic license applications 2006-2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
DeMuro C, Mordin M, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
Mordin MM, Lewis SA, Gnanasakthy A, DeMuro-Mercon CJ, Copley-Merriman K, Fehnel SE. Patient-reported outcomes in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 1, 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A-17-8.
Mordin M, Lewis SE, Gnanasakthy A, Demuro-Mercon C, Copley-Merriman K, Fehnel S. Patient-reported outcomes as mentioned in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 4, 2010. [abstract] Value Health. 2010 May; 13(3):A17-8.
Gnanasakthy A, DeMuro C, Mordin M, Copley-Merriman K, Mauskopf J. The role of the patient voice in health technology assessment. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A19. doi: 10.1016/S1098-3015(10)72074-X
Mordin MM, Clark M, Siersma CA, Copley-Merriman K, Gnanasakthy A. Impact of the FDA draft guidance on patient reported outcomes (PRO) label claims for approved drug products in the US: has it made a difference? Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 19, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A29.